Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults

A. Gupta (London, United Kingdom), J. Steinfeld (Philadelphia, PA, United States of America), R. Price (Stevenage, Hertfordshire, United Kingdom), J. Azmi (Stockley Park, Uxbridge, United Kingdom), E. Bradford (Research Triangle Park, NC, United States of America), S. Yancey (Research Triangle Park, NC, United States of America)

Source: International Congress 2018 – New developments in paediatric asthma
Session: New developments in paediatric asthma
Session type: Poster Discussion
Number: 5447
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Gupta (London, United Kingdom), J. Steinfeld (Philadelphia, PA, United States of America), R. Price (Stevenage, Hertfordshire, United Kingdom), J. Azmi (Stockley Park, Uxbridge, United Kingdom), E. Bradford (Research Triangle Park, NC, United States of America), S. Yancey (Research Triangle Park, NC, United States of America). Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults. 5447

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: